Stockreport

Eledon sees promising data for tegoprubart in islet transplant type 1 diabetes. [Seeking Alpha]

Eledon Pharmaceuticals, Inc.  (ELDN) 
PDF In a 12-patient cohort, 10 out of 12 individuals saw 100% insulin independence 4 weeks after transplant. Also, there were no indications of graft rejection or de novo [Read more]